Is Enanta Pharmaceuticals, Inc. (ENTA) a Buy, Sell, or Hold?
NASDAQ : ENTA
Enanta Pharmaceuticals, Inc. — News
$13.77 USD
$0.43 (3.22%)
- Volume
- 182.99K
- Average Volume
- 171.4K
- Market Capitalization
- $400.41M
- P/E Ratio
- -5.03
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $17.15
- Year Low
- $6.45
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.84
| Source | Headline |
|---|---|
|
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 2026-06-24 10:16:11 |
|
Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older. businesswire.com - 2026-06-23 05:10:00 |
|
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b portion of the trial will confi. businesswire.com - 2026-06-18 07:00:00 |
|
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections gurufocus.com - 2026-05-28 08:00:00 |
|
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live w. businesswire.com - 2026-05-28 07:00:00 |
|
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.06 per share a year ago. zacks.com - 2026-05-11 18:10:18 |
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient or. businesswire.com - 2026-05-11 16:01:00 |
